FindTrial
Sign In

Effects of ultrasound-guided stellate ganglion block on perioperative recovery in advanced gastric cancer and its combined effect with postoperative chemotherapy-immunotherapy on long-term outcomes: a single-center, randomized controlled clinical trial

Effects of ultrasound-guided stellate ganglion block on perioperative recovery in advanced gastric cancer and its combined effect with postoperative chemotherapy-immunotherapy on long-term outcomes: a single-center, randomized controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118204
Enrollment
Unknown
Registered
2026-02-03
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced gastric cancer

Interventions

SGB:Ultrasound-guided right-sided SGB (with standardized perioperative frequency) + standard perioperative/postoperative management (including the planned postoperative chemotherapy and immunotherapy
Control Group:The Control group received an equal dose/frequency of saline solution + standard perioperative/postoperative management (including the planned postoperative chemotherapy + immunotherapy

Sponsors

The Second Hospital & Clinical Medical School, Lanzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18–75 years; 2. Meeting the diagnostic criteria for gastric cancer; 3. Pathologically/clinically staged as II–III gastric cancer (without distant metastasis), scheduled to undergo laparoscopic radical surgery and expected to receive standard adjuvant chemotherapy + immunotherapy postoperatively; 4. ASA classification I–III; 5. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe cardiac, pulmonary, hepatic, or renal dysfunction; 2. History of central nervous system diseases; 4. Gastric cancer patients with distant metastasis; 5. Coagulation disorders or ongoing anticoagulant therapy; 6. History of thoracic or abdominal surgery; 7. Allergy to ropivacaine; 8. Pregnancy or lactation; 9. History of other prior malignancies; 10. Planned relocation away from the study area postoperatively or inability to complete scheduled follow-up.

Design outcomes

Primary

MeasureTime frame
2-year disease-free survival rate;—

Secondary

MeasureTime frame
Major complications within 30 days postoperatively;Total postoperative hospital stay ;Time to first passage of flatus ;Quality of Recovery-15 Score;Peripheral Blood Inflammatory Markers;Pittsburgh Sleep Quality Index Score;3-year disease-free survival rate;5-year Overall Survival Rate;—

Countries

China

Contacts

Public ContactZeping Huang

The Second Hospital & Clinical Medical School, Lanzhou University

Ldyy_huangzp@lzu.edu.cn+86 182 1981 1298

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026